<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680283</article-id><article-id pub-id-type="doi">10.3390/v16121851</article-id><article-id pub-id-type="publisher-id">viruses-16-01851</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Possible Protective Effect of IgA Against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) in Bronchoalveolar Lavage in COVID-19 Patients Admitted to Intensive Care Unit</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8814-0953</contrib-id><name><surname>Di Stefano</surname><given-names>Mariantonietta</given-names></name><xref rid="af1-viruses-16-01851" ref-type="aff">1</xref><xref rid="c1-viruses-16-01851" ref-type="corresp">*</xref><xref rid="fn1-viruses-16-01851" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Mirabella</surname><given-names>Lucia</given-names></name><xref rid="af2-viruses-16-01851" ref-type="aff">2</xref><xref rid="fn1-viruses-16-01851" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Cotoia</surname><given-names>Antonella</given-names></name><xref rid="af2-viruses-16-01851" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5969-3890</contrib-id><name><surname>Faleo</surname><given-names>Giuseppina</given-names></name><xref rid="af1-viruses-16-01851" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9718-7454</contrib-id><name><surname>Rauseo</surname><given-names>Michela</given-names></name><xref rid="af2-viruses-16-01851" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Rizzo</surname><given-names>Anna Chiara</given-names></name><xref rid="af2-viruses-16-01851" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Fiore</surname><given-names>Jos&#x000e8; Ramon</given-names></name><xref rid="af1-viruses-16-01851" ref-type="aff">1</xref><xref rid="fn2-viruses-16-01851" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9864-2893</contrib-id><name><surname>Cinnella</surname><given-names>Gilda</given-names></name><xref rid="af2-viruses-16-01851" ref-type="aff">2</xref><xref rid="fn2-viruses-16-01851" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6424-7841</contrib-id><name><surname>Serviddio</surname><given-names>Gaetano</given-names></name><xref rid="af3-viruses-16-01851" ref-type="aff">3</xref><xref rid="fn2-viruses-16-01851" ref-type="author-notes">&#x02021;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ramos-Lopez</surname><given-names>Irene</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01851"><label>1</label>Department of Surgical and Medical Science, Section of Infectious Diseases, University of Foggia, 71122 Foggia, Italy; <email>giuseppina.faleo@unifg.it</email> (G.F.); <email>jose.fiore@unifg.it</email> (J.R.F.)</aff><aff id="af2-viruses-16-01851"><label>2</label>Anesthesia and Intensive Care Unit, Department of Surgical and Medical Science, Policlinico Riuniti di Foggia, University of Foggia, 71122 Foggia, Italy; <email>lucia.mirabella@unifg.it</email> (L.M.); <email>antonella.cotoia@unifg.it</email> (A.C.); <email>michela.rauseo@unifg.it</email> (M.R.); <email>annachiararizzo91@gmail.com</email> (A.C.R.); <email>gilda.cinnella@unifg.it</email> (G.C.)</aff><aff id="af3-viruses-16-01851"><label>3</label>C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy; <email>gaetano.serviddio@unifg.it</email></aff><author-notes><corresp id="c1-viruses-16-01851"><label>*</label>Correspondence: <email>mariantonietta.distefano@unifg.it</email>; Tel.: +39-338-3022113</corresp><fn id="fn1-viruses-16-01851"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn><fn id="fn2-viruses-16-01851"><label>&#x02021;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1851</elocation-id><history><date date-type="received"><day>17</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>SARS-CoV-2 infection induces a humoral immune response, producing virus-specific antibodies such as IgM, IgG, and IgA. IgA antibodies are present at mucosal sites, protecting against respiratory and other mucosal infections, including SARS-CoV-2, by neutralizing viruses or impeding attachment to epithelial cells. Since SARS-CoV-2 spreads through the nasopharynx, the specific IgAs of SARS-CoV-2 are produced quickly after infection, effectively contributing to virus neutralization. Dimeric IgA has been reported to be 10 to 15 times more potent than its equivalent IgG, suggesting that this isotype may be particularly interesting in developing new monoclonal antibodies and/or new vaccines efficiently neutralizing the virus at the mucosal sites. It is still unclear whether IgA antibodies in BAL might play a role in the disease course and if their presence may have a prognostic significance. However, a harmful effect on diseases with high IgA titers has been reported. This study evaluated mucosal-specific IgA and IgG profiles in BAL of patients with COVID-19 acute respiratory failure admitted to the ICU. We included 57 patients (41 males and 16 females), admitted to the ICU of the University of Foggia. We used a commercially available ELISA assay to evaluate the presence of SARS-CoV-2 IgG and IgA antibodies in plasma and BAL of the 57 hospitalized patients with severe COVID-19 respiratory failure. However, 40/57 BAL and plasma from infected patients were available for the ELISA test; the remaining specimens were unsuitable. IgG and IgA antibodies against SARS-CoV-2 were detectable in 37 (92.5%) and 40 (100%) plasma specimens, respectively. IgG antibodies were found in a single sample, while IgAs were detected in 19 of 40 BAL samples analyzed. Correlations between these parameters and patient outcomes reveal a signature associated with survival. Interestingly, a statistically significant inverse correlation was found between the mortality rate and the presence of IgA to SARS-CoV-2 in BAL specimens. None of the 19 patients with a positive IgA died, compared to 7 out of 12 patients with a negative IgA-BAL (<italic toggle="yes">p</italic>: &#x0003c;0.0004). Despite being limited in size, this study suggests a significant protective effect of mucosal immunity in COVID-19 patients, even in advanced disease stages, and a role of IgA in the defense against the virus, as well as the possible use of effective vaccines and therapeutic strategies based on IgA antibodies.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>anti-SARS-CoV-2 IgA</kwd><kwd>anti-SARS-CoV-2 IgG</kwd><kwd>bronchoalveolar lavage (BAL)</kwd><kwd>SOFA score</kwd><kwd>APACHE II score</kwd></kwd-group><funding-group><award-group><funding-source>European Union&#x02014;NextGenerationUE as part of PNRR MUR&#x02014;M4C2&#x02014;Investimento 1.3&#x02014;Public Call &#x0201c;PartenariatiEstesi&#x0201d;</funding-source><award-id>341/2022</award-id></award-group><award-group><funding-source>Progetto HEAL ITALIA &#x0201c;Health Extended Alliance for Innovative Therapies, Advanced Lab-research</funding-source></award-group><award-group><funding-source>Integrated Approaches of Precision Medicine&#x0201d;-acronimo HEAL ITALIA</funding-source><award-id>PE_00000019-CUP D73C22001230006</award-id></award-group><funding-statement>The author recognizes the financial contribution of the European Union&#x02014;NextGenerationUE as part of PNRR MUR&#x02014;M4C2&#x02014;Investimento 1.3&#x02014;Public Call &#x0201c;PartenariatiEstesi&#x0201d;&#x02014;D.D.n. 341/2022 and Progetto HEAL ITALIA &#x0201c;Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine&#x0201d;-acronimo HEAL ITALIA (codice domanda PE_00000019-CUP D73C22001230006).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01851"><title>1. Introduction</title><p>SARS-CoV-2 infection induces a humoral immune response, producing virus-specific antibodies such as IgM, IgG, and IgA.</p><p>IgA antibodies in mucosal sites protect against respiratory and other mucosal infections by neutralizing viruses or impeding attachment to epithelial cells [<xref rid="B1-viruses-16-01851" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01851" ref-type="bibr">2</xref>]. The immunoglobulin distribution on the mucosa differs from that in serum: In serum, IgG is the dominating isotype (75&#x02013;80% of serum immunoglobulins) followed by IgA (15%) and IgM (10%) [<xref rid="B3-viruses-16-01851" ref-type="bibr">3</xref>]. In contrast, on the mucosa, IgA is the predominant class (~74% of all mucosa immunoglobulin) followed by IgG (~25%) and IgM (~2%) [<xref rid="B3-viruses-16-01851" ref-type="bibr">3</xref>]. The overall production of IgA (40&#x02013;60 mg/kg per day) is higher than all other isotypes [<xref rid="B3-viruses-16-01851" ref-type="bibr">3</xref>]. Consistently, with the fact that SARS-CoV-2 spreads through the nasopharynx, the specific IgAs of SARS-CoV-2 are produced quickly at this level after infection, contributing effectively to the neutralization of the virus. Dimeric IgAs have been reported to be 10 to 15 times more potent than their equivalent IgG, suggesting that this isotype may be particularly interesting in developing either new treatment strategies by plasma-derived or monoclonal antibodies and/or new vaccine approaches based on IgA production that can neutralize the virus [<xref rid="B3-viruses-16-01851" ref-type="bibr">3</xref>,<xref rid="B4-viruses-16-01851" ref-type="bibr">4</xref>].</p><p>IgA can be found in the early phase of SARS-CoV-2 infection [<xref rid="B5-viruses-16-01851" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01851" ref-type="bibr">6</xref>]. However, the role of mucosal IgA in response to SARS-CoV-2 infection is still unclear. In mice, vaccination with SARS-CoV-2 proteins induces localized and systemic SARS-CoV-2 challenge suggesting that mucosal-induced IgA is protective [<xref rid="B7-viruses-16-01851" ref-type="bibr">7</xref>].</p><p>Kim and collaborators generated a recombinant adenovirus-based vaccine candidate against MERS-CoV inducing IgG and secretory IgA and providing long-lasting neutralizing immunity [<xref rid="B8-viruses-16-01851" ref-type="bibr">8</xref>]. Recently, two intramuscular vaccinations with mRNA-based vaccines induced systemic circulating IgA anti-FLS and anti-RBD response against SARS-CoV-2 [<xref rid="B9-viruses-16-01851" ref-type="bibr">9</xref>].</p><p>In this study, higher IgA anti-SARS-CoV-2 S levels were associated with protection from breakthrough infection [<xref rid="B9-viruses-16-01851" ref-type="bibr">9</xref>].</p><p>From a clinical point of view in a large-scale cohort, it was demonstrated that subjects with selective IgA deficiency have higher rates of COVID-19 disease and re-infection, which demonstrated a very likely role of mucosal immunity in protecting against SARS-CoV-2 [<xref rid="B10-viruses-16-01851" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01851" ref-type="bibr">11</xref>].</p><p>On the other hand, data from Ruiz [<xref rid="B12-viruses-16-01851" ref-type="bibr">12</xref>] revealed that the antibody persistence, and not the amount, may play an adverse role in COVID-19 pathogenesis; in fact, analyses of IgG and IgA response varied with the patient&#x02019;s outcome.</p><p>S2-specific IgG resulted higher in survivors than non-survivors, whereas S1-specific IgA and sustained levels of S1, RBD, S2, and NP-specific IgG once SARS-CoV-2 was cleared from the lungs were associated with fatal outcomes. The presence of these antibodies in BAL samples in non-survivor patients persists, suggesting that persistent spike- and NP-specific antibodies are non-neutralizing [<xref rid="B12-viruses-16-01851" ref-type="bibr">12</xref>].</p><p>Although in the early phase of the infection, much of the neutralizing activity in plasma is in samples with IgM and IgA fraction [<xref rid="B13-viruses-16-01851" ref-type="bibr">13</xref>,<xref rid="B14-viruses-16-01851" ref-type="bibr">14</xref>]. However, IgG antibodies to the spike protein are present at the highest level in circulation after several months compared to IgA and IgM antibodies that decline rapidly after the first-month post-outbreak of the disease.</p><p>It is still unclear whether the IgA antibodies at the mucosal site, in the lung, that we can explore by BAL evaluation, might play a role in the course of the disease and if their presence may have a prognostic significance.</p><p>The study aimed to evaluate the profile of the mucosal-specific IgA and IgG in BAL of patients with COVID-19 acute respiratory failure admitted in the ICU. Correlations between these parameters and patient clinical outcomes reveal a signature associated with survival.</p></sec><sec id="sec2-viruses-16-01851"><title>2. Material and Methods</title><sec id="sec2dot1-viruses-16-01851"><title>2.1. Study Population</title><p>Fifty-seven patients were admitted to the ICU of the University of Foggia with a diagnosis of acute respiratory failure, between March 2021 and May 2021. All patients had a severe acute respiratory syndrome coronavirus 2 infection confirmed by the virus in RT PCR from nasopharyngeal swabs, intubation, mechanical ventilation, and a diagnosis of COVID-19. The patients with SARS-CoV-2-negative pneumonia were used as negative controls.</p><p>Recorded data included demographics [age, gender, and body mass index (BMI)], comorbidities, previous pharmacological treatments, disease chronology [time from onset of symptoms and hospital admission to initiation of respiratory support, and ICU length of stay (LOS)], symptoms at ICU admission, vital signs [temperature, mean arterial pressure (MAP), and heart rate], laboratory parameters (blood test, coagulation, and biochemical), non-respiratory sequential organ failure assessment (non-respiratory SOFA) and APACHE II scores [<xref rid="B15-viruses-16-01851" ref-type="bibr">15</xref>,<xref rid="B16-viruses-16-01851" ref-type="bibr">16</xref>], and hospital mortality. The patients were managed according to the recommendations for COVID-19-induced acute respiratory failure.</p></sec><sec sec-type="subjects" id="sec2dot2-viruses-16-01851"><title>2.2. IgA and IgG from BAL and Serum of Patients</title><p>About 57 BAL from SARS-CoV-2-infected and 10 from non-infected individuals were collected in the ICU and processed as described elsewhere [<xref rid="B17-viruses-16-01851" ref-type="bibr">17</xref>]. IgA against a recombinant S1 domain of the SARS-CoV-2 was detected using Anti-SARS-CoV-2-ELISA IgA and IgG (Euroimmun Medizinische Laboradiagnostika, Luebeck, Germany, EI 2606-9601A IgA, EI 2606-9601G).</p><p>The enzyme-linked immunosorbent assay (ELISA) provides semi-quantitative in vitro determination of human antibodies of immunoglobulin classes IgA and IgG against SARS-CoV-2 (The EUROIMMUN Anti-SARS-CoV-2 Assay), which was used as previously described [<xref rid="B18-viruses-16-01851" ref-type="bibr">18</xref>]</p><p>Chi-Square and Fisher tests were used to investigate the relationship between the presence of IgA antibodies in SARS-CoV-2-infected patients and age, comorbidities, the SOFA and APACHE II scores, and survival. A <italic toggle="yes">p</italic>-value of less than 0.05 was considered significant.</p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01851"><title>3. Results</title><p>The clinical characteristics of the patients enrolled in the study are summarized in <xref rid="viruses-16-01851-t001" ref-type="table">Table 1</xref>.</p><p>Fifty-seven patients were included, 41 males (72%) and 16 females (28%). The enrolled population had a mean age of 70.04 years &#x000b1; 9.43 years.</p><p>Among our study group, all patients had comorbidities such as diabetes, hypertension, obesity, cardiovascular diseases, COPD (chronic obstructive pulmonary disease), allergy, renal failure cancer, asthma, and liver disease.</p><p>Of the study group, 22 of 57 infected patients had direct access to the ICU.</p><p>Thirty-five patients (61%) were initially referred to the Infectious Diseases, Pneumology, or Internal Medicine department and subsequently transferred to the ICU when clinical conditions worsened.</p><p>We assessed the presence of IgG and IgA antibodies recognizing the SARS-CoV-2 S1 protein in both BAL and plasma samples from 40 of 57 infected patients. Anti-SARS-CoV-2 IgG and IgA were detected in 37 (91.5%) and 40 (100%) plasma samples, respectively. In addition, anti-SARS-CoV-2 IgG was detected in one BAL sample (2.5%), while IgA antibodies were present in the BAL samples of 19 patients.</p><p>We evaluated the recovery rates for anti-SARS-CoV-2 IgA among a group of patients who were monitored at two time points. In two patients, IgA antibodies were detected in both sequential BAL samples. A patient showed the absence of antibodies in the first sample followed by an increase in IgA antibodies in the second sample. In four patients, however, IgA antibodies were not detected in any BAL samples.</p><p>There was no significant correlation (<italic toggle="yes">p</italic> &#x02265; 0.5) between patients with higher APACHE II scores and the absence of IgA antibodies.</p><p>Furthermore, no differences were found between populations with and without IgA and a lower SOFA score. A patient with a higher SOFA score and with anti-SARS-CoV-2-IgA had a fatal outcome.</p><p>A significant correlation between the presence of anti-SARS-CoV-2 IgA and the survival of the patients entering the ICU was demonstrated (<italic toggle="yes">p</italic>-value: &#x0003c;0.000496).</p><p>The age of the patients played a role in the development of the anti-SARS-CoV-2 IgA; in fact, the data indicated an absence of antibodies in the patients with a higher age (<italic toggle="yes">p</italic>-value &#x0003c; 0.013).</p><p>Most patients survived if their APACHE II scores were 9 or less during the first 48 h. Patients with APACHE II scores of 13 or more were at a high risk of death. The sensitivity rate at admission is between 34% and 70%, and the specificity rate is between 76% and 98%.</p><p>Mortality is more likely to occur if the SOFA score is higher. Regarding the SOFA score, the maximum score in our population was 10.</p><p>Regarding APACHE II: 14 (24%) patients had a score between 0 and 10. Of those, 8 showed anti-SARS-CoV-2 IgAs in BAL; 38 (67%) had a score between 11 and 20, and 10 were positive for the presence of IgA antibodies. Only five individuals (9% of the population) had a score higher than 21, and one showed IgA antibodies in BAL (<xref rid="viruses-16-01851-t002" ref-type="table">Table 2</xref>, <xref rid="viruses-16-01851-f001" ref-type="fig">Figure 1</xref> and <xref rid="viruses-16-01851-f002" ref-type="fig">Figure 2</xref>).</p><p>Regarding the SOFA, 26 patients (46%) showed a score between 0 and 3, and 9 were positive for IgA antibodies. Of 29 patients, 9 with scores between 4 and 7 were positive for antibodies. Only one patient with a score between 8 and 10 displayed the presence of IgA in BAL.</p></sec><sec><title>4. Discussion</title><p>Little information is available on the immune response during SARS-CoV-2 infection at the mucosal level, including the respiratory tract where the virus enters and replicates.</p><p>It has been reported that mucosal IgAs play an important role in the defense against both COVID-19 and influenza infections by providing mucosal immunity neutralizing the viruses, preventing viral entry, and reducing their transmission [<xref rid="B19-viruses-16-01851" ref-type="bibr">19</xref>,<xref rid="B20-viruses-16-01851" ref-type="bibr">20</xref>]. IgA antibodies are produced by plasma cells in the mucosal-associated lymphoid tissues (MALTs) and are secreted into the respiratory tract [<xref rid="B21-viruses-16-01851" ref-type="bibr">21</xref>].</p><p>In humans, IgAs are present in two subclasses: IgA1 (mainly present in serum) and IgA2 (mainly observed at the mucosal level). Although mucosal (secretory) IgA is dimeric, serum IgA is composed mainly of monomers. However, they also differ in their hinge region and the glycosylation sites. IgA2 antibodies play a role in the pro-inflammatory activation of neutrophils and macrophages concerning the IgA1s. In serum, IgA1 is the principal, while in the mucosa, IgA2s are more present [<xref rid="B22-viruses-16-01851" ref-type="bibr">22</xref>,<xref rid="B23-viruses-16-01851" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01851" ref-type="bibr">24</xref>].</p><p>We know that individuals affected by selective IgA deficiency (sIgAD) (the most common primary immunodeficiency disorder) were suggested to be at higher risk of severe COVID-19, which is much stronger evidence of disease susceptibility [<xref rid="B11-viruses-16-01851" ref-type="bibr">11</xref>]. This seems to emphasize the potential prognostic role of IgA in SARS-CoV-2 infection. According to Padoan and collaborators [<xref rid="B25-viruses-16-01851" ref-type="bibr">25</xref>], the IgA response appears and grows early, with a stronger and more persistent response than the IgM response. The authors, further, suggest performing additional longitudinal research on the function and protection efficacy of virus-specific antibodies over time [<xref rid="B25-viruses-16-01851" ref-type="bibr">25</xref>].</p><p>In the BAL, secretory IgA and IgG are produced locally before entering the alveolar space, and their antigenic repertoire is different from that of the serum humoral response [<xref rid="B26-viruses-16-01851" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01851" ref-type="bibr">27</xref>,<xref rid="B28-viruses-16-01851" ref-type="bibr">28</xref>]. Few reports are nevertheless still available about the presence of IgA antibodies in COVID-19 disease [<xref rid="B29-viruses-16-01851" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01851" ref-type="bibr">30</xref>].</p><p>In this study, we investigated the presence of anti-SARS-CoV-2 IgG and IgA in both plasma and BAL specimens of hospitalized patients with severe pneumonia who were subjected to oxygen therapy, which was replaced by orotracheal intubation (IOT).</p><p>Anti-SARS-CoV-2 IgG was observed in 1 of 40 BAL samples (2.1%), while IgA antibodies were found in 19 of 40 (47.5%) patients&#x02019; BAL specimens. These data indicate that IgA to SARS-CoV-2 can be found in the lung mucosa in the later stages of COVID-19, which may contribute to viral clearance.</p><p>We observed that the detection of IgA in BAL was significantly correlated with survival, which is contrary to the results from Ruiz and collaborators [<xref rid="B12-viruses-16-01851" ref-type="bibr">12</xref>] who reported IgA presence in BAL as a negative prognostic factor. Differences in patient selection, different pandemic periods (2020 vs 2021), different circulating viral variants, possible interference from vaccination initiated, and the use of antivirals could partly explain these discrepancies.</p><p>In addition, anti-SARS-CoV-2 IgG and IgA were detected in 37 (91.5%) and 40 (100%) plasma samples, respectively. Although we did not examine the timing of the appearance of IgA and IgG, we are in line with the results by Zervous and collaborators who demonstrated IgG and IgA positivity in most patients tested, with an increase of 100% on day 21 for IgG while IgA antibodies were highest in patients with a severe and critical illness [<xref rid="B31-viruses-16-01851" ref-type="bibr">31</xref>].</p><p>Furthermore, a study demonstrated a decrease in serum IgA in COVID-19 patients with pneumonia compared to patients with a mild course of disease [<xref rid="B2-viruses-16-01851" ref-type="bibr">2</xref>], supporting the important role of these antibodies&#x02019; mediated immunity for disease outcome.</p><p>SIgA plays an outstanding role in mucosal immunity and its function is impaired in several inflammatory lung diseases [<xref rid="B3-viruses-16-01851" ref-type="bibr">3</xref>]. Therefore, supplementation with therapeutic IgA antibodies [<xref rid="B32-viruses-16-01851" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01851" ref-type="bibr">33</xref>] might be a worthwhile strategy. In conclusion, our findings, although limited in size, support the protective role of IgA immune response in COVID-19 patients in survival, even in advanced stages of the disease. Furthermore, we suggest continuing the study to designate IgA as a promising therapeutic agent for the treatment of inflammatory lung diseases.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>M.D.S., J.R.F., L.M., G.C. and G.S. planned and supervised the project and the manuscript writing; M.D.S., G.F. and A.C.R. processed samples and performed ELISA test and statistical analysis; J.R.F., L.M., A.C., M.R. and G.C. collected and supervised the clinical assessment. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted with the Declaration of Helsinki and approved by the Ethics Committee of Policlinico &#x0201c;OORR&#x0201d; of Foggia (Protocol number 8/CE/2020). </p></notes><notes><title>Informed Consent Statement</title><p>The patients signed a written informed consent in agreement with the WMA Helsinki declaration.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are available on request to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01851"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montague</surname><given-names>B.T.</given-names></name>
<name><surname>Wipperman</surname><given-names>M.F.</given-names></name>
<name><surname>Chio</surname><given-names>E.</given-names></name>
<name><surname>Crow</surname><given-names>R.</given-names></name>
<name><surname>Hooper</surname><given-names>A.T.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>M.P.</given-names></name>
<name><surname>Sim&#x000f5;es</surname><given-names>E.A.F.</given-names></name>
</person-group><article-title>Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>14932</elocation-id><!--<pub-id pub-id-type="pmcid">PMC9437396</pub-id>--><pub-id pub-id-type="doi">10.1038/s41598-022-19095-7</pub-id><pub-id pub-id-type="pmid">36056118</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01851"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>S.L.</given-names></name>
<name><surname>Tyagi</surname><given-names>R.</given-names></name>
<name><surname>Dhar</surname><given-names>A.</given-names></name>
<name><surname>Oswal</surname><given-names>N.</given-names></name>
<name><surname>Khandelwal</surname><given-names>A.</given-names></name>
<name><surname>Jaiswal</surname><given-names>R.K.</given-names></name>
</person-group><article-title>Children&#x02019;s SARS-CoV-2 Infection and Their Vaccination</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>418</elocation-id><!--<pub-id pub-id-type="pmcid">PMC9962844</pub-id>--><pub-id pub-id-type="doi">10.3390/vaccines11020418</pub-id><pub-id pub-id-type="pmid">36851295</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01851"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bohl&#x000e4;nder</surname><given-names>F.</given-names></name>
</person-group><article-title>A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1127339</elocation-id><!--<pub-id pub-id-type="pmcid">PMC10083398</pub-id>--><pub-id pub-id-type="doi">10.3389/fimmu.2023.1127339</pub-id><pub-id pub-id-type="pmid">37051237</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01851"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pantaleo</surname><given-names>G.</given-names></name>
<name><surname>Correia</surname><given-names>B.</given-names></name>
<name><surname>Fenwick</surname><given-names>C.</given-names></name>
<name><surname>Joo</surname><given-names>V.S.</given-names></name>
<name><surname>Perez</surname><given-names>L.</given-names></name>
</person-group><article-title>Antibodies to combat viral infections: Development strategies and progress</article-title><source>Nat. Rev. Drug Discov.</source><year>2022</year><volume>21</volume><fpage>676</fpage><lpage>696</lpage><!--<pub-id pub-id-type="pmcid">PMC9207876</pub-id>--><pub-id pub-id-type="doi">10.1038/s41573-022-00495-3</pub-id><pub-id pub-id-type="pmid">35725925</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01851"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sterlin</surname><given-names>D.</given-names></name>
<name><surname>Mathian</surname><given-names>A.</given-names></name>
<name><surname>Miyara</surname><given-names>M.</given-names></name>
<name><surname>Mohr</surname><given-names>A.</given-names></name>
<name><surname>Anna</surname><given-names>F.</given-names></name>
<name><surname>Cla&#x000eb;r</surname><given-names>L.</given-names></name>
<name><surname>Quentric</surname><given-names>P.</given-names></name>
<name><surname>Fadlallah</surname><given-names>J.</given-names></name>
<name><surname>Devilliers</surname><given-names>H.</given-names></name>
<name><surname>Ghillani</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>IgA dominates the early neutralizing antibody response to SARS-CoV-2</article-title><source>Sci. Transl. Med.</source><year>2021</year><volume>13</volume><fpage>eabd2223</fpage><!--<pub-id pub-id-type="pmcid">PMC7857408</pub-id>--><pub-id pub-id-type="doi">10.1126/scitranslmed.abd2223</pub-id><pub-id pub-id-type="pmid">33288662</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01851"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esmat</surname><given-names>K.</given-names></name>
<name><surname>Jamil</surname><given-names>B.</given-names></name>
<name><surname>Kheder</surname><given-names>R.K.</given-names></name>
<name><surname>Kombe</surname><given-names>A.J.</given-names></name>
<name><surname>Zeng</surname><given-names>W.</given-names></name>
<name><surname>Ma</surname><given-names>H.</given-names></name>
<name><surname>Jin</surname><given-names>T.</given-names></name>
</person-group><article-title>Immunoglobulin A response to SARS-CoV-2 infection and immunity</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e24031</fpage><!--<pub-id pub-id-type="pmcid">PMC10789627</pub-id>--><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e24031</pub-id><pub-id pub-id-type="pmid">38230244</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01851"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Izikson</surname><given-names>R.</given-names></name>
<name><surname>Brune</surname><given-names>D.</given-names></name>
<name><surname>Bolduc</surname><given-names>J.S.</given-names></name>
<name><surname>Bourron</surname><given-names>P.</given-names></name>
<name><surname>Fournier</surname><given-names>M.</given-names></name>
<name><surname>Moore</surname><given-names>T.M.</given-names></name>
<name><surname>Pandey</surname><given-names>A.</given-names></name>
<name><surname>Perez</surname><given-names>L.</given-names></name>
<name><surname>Sater</surname><given-names>N.</given-names></name>
<name><surname>Shrestha</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged &#x02265;65 years: A phase 2, randomized, open-label study</article-title><source>Lancet Respir. Med.</source><year>2022</year><volume>10</volume><fpage>392</fpage><lpage>402</lpage><!--<pub-id pub-id-type="pmcid">PMC8803382</pub-id>--><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00557-9</pub-id><pub-id pub-id-type="pmid">35114141</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01851"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>M.H.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Chang</surname><given-names>J.</given-names></name>
</person-group><article-title>Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus</article-title><source>PLoS ONE.</source><year>2019</year><volume>14</volume><elocation-id>e0220196</elocation-id><!--<pub-id pub-id-type="pmcid">PMC6645677</pub-id>--><pub-id pub-id-type="doi">10.1371/journal.pone.0220196</pub-id><pub-id pub-id-type="pmid">31329652</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01851"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Norton</surname><given-names>N.J.</given-names></name>
<name><surname>Ings</surname><given-names>D.P.</given-names></name>
<name><surname>Fifield</surname><given-names>K.E.</given-names></name>
<name><surname>Barnes</surname><given-names>D.A.</given-names></name>
<name><surname>Barnable</surname><given-names>K.A.</given-names></name>
<name><surname>Harnum</surname><given-names>D.O.A.</given-names></name>
<name><surname>Holder</surname><given-names>K.A.</given-names></name>
<name><surname>Russell</surname><given-names>R.S.</given-names></name>
<name><surname>Grant</surname><given-names>M.D.</given-names></name>
</person-group><article-title>Characteristics of Vaccine- and Infection-Induced Systemic IgA Anti-SARS-CoV-2 Spike Responses</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1462</elocation-id><!--<pub-id pub-id-type="pmcid">PMC10537135</pub-id>--><pub-id pub-id-type="doi">10.3390/vaccines11091462</pub-id><pub-id pub-id-type="pmid">37766138</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01851"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magen</surname><given-names>E.</given-names></name>
<name><surname>Merzon</surname><given-names>E.</given-names></name>
<name><surname>Green</surname><given-names>I.</given-names></name>
<name><surname>Golan-Cohen</surname><given-names>A.</given-names></name>
<name><surname>Vinker</surname><given-names>S.</given-names></name>
<name><surname>Israel</surname><given-names>A.</given-names></name>
</person-group><article-title>Selective IgA deficiency and COVID-19</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2023</year><volume>11</volume><fpage>1936</fpage><lpage>1938</lpage><!--<pub-id pub-id-type="pmcid">PMC9970652</pub-id>--><pub-id pub-id-type="doi">10.1016/j.jaip.2023.02.016</pub-id><pub-id pub-id-type="pmid">36858279</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01851"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000c7;&#x000f6;lkesen</surname><given-names>F.</given-names></name>
<name><surname>Kandemir</surname><given-names>B.</given-names></name>
<name><surname>Arslan</surname><given-names>&#x0015e;.</given-names></name>
<name><surname>&#x000c7;&#x000f6;lkesen</surname><given-names>F.</given-names></name>
<name><surname>Y&#x00131;ld&#x00131;z</surname><given-names>E.</given-names></name>
<name><surname>Korkmaz</surname><given-names>C.</given-names></name>
<name><surname>Vatansev</surname><given-names>H.</given-names></name>
<name><surname>Evcen</surname><given-names>R.</given-names></name>
<name><surname>Aykan</surname><given-names>F.S.</given-names></name>
<name><surname>K&#x00131;l&#x00131;n&#x000e7;</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Relationship between Selective IgA Deficiency and COVID-19 Prognosis</article-title><source>Jpn. J. Infect. Dis.</source><year>2022</year><volume>75</volume><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.7883/yoken.JJID.2021.281</pub-id><pub-id pub-id-type="pmid">34588364</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01851"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruiz</surname><given-names>M.J.</given-names></name>
<name><surname>Siracusano</surname><given-names>G.</given-names></name>
<name><surname>Cottignies-Calamarte</surname><given-names>A.</given-names></name>
<name><surname>Tudor</surname><given-names>D.</given-names></name>
<name><surname>Real</surname><given-names>F.</given-names></name>
<name><surname>Zhu</surname><given-names>A.</given-names></name>
<name><surname>Pastori</surname><given-names>C.</given-names></name>
<name><surname>Capron</surname><given-names>C.</given-names></name>
<name><surname>Rosenberg</surname><given-names>A.R.</given-names></name>
<name><surname>Temperton</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1&#x003b2; associate with COVID-19 fatal outcome: A cross-sectional analysis</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>842468</elocation-id><!--<pub-id pub-id-type="pmcid">PMC9560774</pub-id>--><pub-id pub-id-type="doi">10.3389/fimmu.2022.842468</pub-id><pub-id pub-id-type="pmid">36248831</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01851"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gasser</surname><given-names>R.M.</given-names></name>
<name><surname>Cloutier</surname><given-names>M.</given-names></name>
<name><surname>Pr&#x000e9;vost</surname><given-names>J.</given-names></name>
<name><surname>Fink</surname><given-names>C.</given-names></name>
<name><surname>Ducas</surname><given-names>&#x000c9;.</given-names></name>
<name><surname>Ding</surname><given-names>S.</given-names></name>
<name><surname>Dussault</surname><given-names>N.</given-names></name>
<name><surname>Landry</surname><given-names>P.</given-names></name>
<name><surname>Tremblay</surname><given-names>T.</given-names></name>
<name><surname>Laforce-Lavoie</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2</article-title><source>Cell Rep.</source><year>2021</year><volume>34</volume><fpage>108790</fpage><!--<pub-id pub-id-type="pmcid">PMC7874916</pub-id>--><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108790</pub-id><pub-id pub-id-type="pmid">33596407</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01851"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verkerke</surname><given-names>H.</given-names></name>
<name><surname>Saeedi</surname><given-names>B.J.</given-names></name>
<name><surname>Boyer</surname><given-names>D.</given-names></name>
<name><surname>Allen</surname><given-names>J.W.</given-names></name>
<name><surname>Owens</surname><given-names>J.</given-names></name>
<name><surname>Shin</surname><given-names>S.</given-names></name>
<name><surname>Horwath</surname><given-names>M.</given-names></name>
<name><surname>Patel</surname><given-names>K.</given-names></name>
<name><surname>Paul</surname><given-names>A.</given-names></name>
<name><surname>Wu</surname><given-names>S.C.</given-names></name>
<etal/>
</person-group><article-title>Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma</article-title><source>Transfusion</source><year>2021</year><volume>61</volume><fpage>1740</fpage><lpage>1748</lpage><!--<pub-id pub-id-type="pmcid">PMC8242454</pub-id>--><pub-id pub-id-type="doi">10.1111/trf.16435</pub-id><pub-id pub-id-type="pmid">34041759</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01851"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vincent</surname><given-names>J.L.</given-names></name>
<name><surname>Moreno</surname><given-names>R.</given-names></name>
<name><surname>Takala</surname><given-names>J.</given-names></name>
<name><surname>Willatts</surname><given-names>S.</given-names></name>
<name><surname>De Mendon&#x000e7;a</surname><given-names>A.</given-names></name>
<name><surname>Bruining</surname><given-names>H.</given-names></name>
<name><surname>Reinhart</surname><given-names>C.K.</given-names></name>
<name><surname>Suter</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine</article-title><source>Intensive Care Med.</source><year>1996</year><volume>22</volume><fpage>707</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1007/BF01709751</pub-id><pub-id pub-id-type="pmid">8844239</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01851"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knaus</surname><given-names>W.A.</given-names></name>
<name><surname>Draper</surname><given-names>E.A.</given-names></name>
<name><surname>Wagner</surname><given-names>D.P.</given-names></name>
<name><surname>Zimmerman</surname><given-names>J.E.</given-names></name>
</person-group><article-title>APACHE II: A severity of disease classification system</article-title><source>Crit. Care Med.</source><year>1985</year><volume>13</volume><fpage>818</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1097/00003246-198510000-00009</pub-id><pub-id pub-id-type="pmid">3928249</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01851"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Delclaux</surname><given-names>C.</given-names></name>
<name><surname>Roupie</surname><given-names>E.</given-names></name>
<name><surname>Blot</surname><given-names>F.</given-names></name>
<name><surname>Brochard</surname><given-names>L.</given-names></name>
<name><surname>Lemaire</surname><given-names>F.</given-names></name>
<name><surname>Brun-Buisson</surname><given-names>C.</given-names></name>
</person-group><article-title>Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: Incidence and diagnosis</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>1997</year><volume>156</volume><issue-part>Pt 1</issue-part><fpage>1092</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.156.4.9701065</pub-id><pub-id pub-id-type="pmid">9351607</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01851"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gededzha</surname><given-names>M.P.</given-names></name>
<name><surname>Mampeule</surname><given-names>N.</given-names></name>
<name><surname>Jugwanth</surname><given-names>S.</given-names></name>
<name><surname>Zwane</surname><given-names>N.</given-names></name>
<name><surname>David</surname><given-names>A.</given-names></name>
<name><surname>Burgers</surname><given-names>W.A.</given-names></name>
<name><surname>Blackburn</surname><given-names>J.M.</given-names></name>
<name><surname>Grove</surname><given-names>J.S.</given-names></name>
<name><surname>George</surname><given-names>J.A.</given-names></name>
<name><surname>Sanne</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><elocation-id>e0252317</elocation-id><!--<pub-id pub-id-type="pmcid">PMC8221517</pub-id>--><pub-id pub-id-type="doi">10.1371/journal.pone.0252317</pub-id><pub-id pub-id-type="pmid">34161348</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01851"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tyagi</surname><given-names>R.</given-names></name>
<name><surname>Basu</surname><given-names>S.</given-names></name>
<name><surname>Dhar</surname><given-names>A.</given-names></name>
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Gupta</surname><given-names>S.L.</given-names></name>
<name><surname>Jaiswal</surname><given-names>R.K.</given-names></name>
</person-group><article-title>Role of Immunoglobulin A in COVID-19 and Influenza Infections</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1647</elocation-id><!--<pub-id pub-id-type="pmcid">PMC10675305</pub-id>--><pub-id pub-id-type="doi">10.3390/vaccines11111647</pub-id><pub-id pub-id-type="pmid">38005979</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01851"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Lorenzi</surname><given-names>J.C.C.</given-names></name>
<name><surname>Muecksch</surname><given-names>F.</given-names></name>
<name><surname>Finkin</surname><given-names>S.</given-names></name>
<name><surname>Viant</surname><given-names>C.</given-names></name>
<name><surname>Gaebler</surname><given-names>C.</given-names></name>
<name><surname>Cipolla</surname><given-names>M.</given-names></name>
<name><surname>Hoffmann</surname><given-names>H.H.</given-names></name>
<name><surname>Oliveira</surname><given-names>T.Y.</given-names></name>
<name><surname>Oren</surname><given-names>D.A.</given-names></name>
<etal/>
</person-group><article-title>Enhanced SARS-CoV-2 neutralization by dimeric IgA</article-title><source>Sci Transl Med.</source><year>2021</year><volume>13</volume><fpage>eabf1555</fpage><!--<pub-id pub-id-type="pmcid">PMC7857415</pub-id>--><pub-id pub-id-type="doi">10.1126/scitranslmed.abf1555</pub-id><pub-id pub-id-type="pmid">33288661</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01851"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bemark</surname><given-names>M.</given-names></name>
<name><surname>Angeletti</surname><given-names>D.</given-names></name>
</person-group><article-title>Know your enemy or find your friend?&#x02014;Induction of IgA at mucosal surfaces</article-title><source>Immunol. Rev.</source><year>2021</year><volume>303</volume><fpage>83</fpage><lpage>102</lpage><!--<pub-id pub-id-type="pmcid">PMC7612940</pub-id>--><pub-id pub-id-type="doi">10.1111/imr.13014</pub-id><pub-id pub-id-type="pmid">34331314</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01851"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Sousa-Pereira</surname><given-names>P.</given-names></name>
<name><surname>Woof</surname><given-names>J.M.</given-names></name>
</person-group><article-title>IgA: Structure, Function, and Developability</article-title><source>Antibodies</source><year>2019</year><volume>8</volume><elocation-id>57</elocation-id><!--<pub-id pub-id-type="pmcid">PMC6963396</pub-id>--><pub-id pub-id-type="doi">10.3390/antib8040057</pub-id><pub-id pub-id-type="pmid">31817406</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01851"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bakema</surname><given-names>J.E.</given-names></name>
<name><surname>van Egmond</surname><given-names>M.</given-names></name>
</person-group><article-title>Immunoglobulin A: A next generation of therapeutic antibodies?</article-title><source>MAbs</source><year>2011</year><volume>3</volume><fpage>352</fpage><lpage>361</lpage><!--<pub-id pub-id-type="pmcid">PMC3218532</pub-id>--><pub-id pub-id-type="doi">10.4161/mabs.3.4.16092</pub-id><pub-id pub-id-type="pmid">21691145</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01851"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woof</surname><given-names>J.M.</given-names></name>
<name><surname>Russell</surname><given-names>M.W.</given-names></name>
</person-group><article-title>Structure and function relationships in IgA</article-title><source>Mucosal Immunol.</source><year>2011</year><volume>4</volume><fpage>590</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1038/mi.2011.39</pub-id><pub-id pub-id-type="pmid">21937984</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01851"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Padoan</surname><given-names>A.</given-names></name>
<name><surname>Sciacovelli</surname><given-names>L.</given-names></name>
<name><surname>Basso</surname><given-names>D.</given-names></name>
<name><surname>Negrini</surname><given-names>D.</given-names></name>
<name><surname>Zuin</surname><given-names>S.</given-names></name>
<name><surname>Cosma</surname><given-names>C.</given-names></name>
<name><surname>Faggian</surname><given-names>D.</given-names></name>
<name><surname>Matricardi</surname><given-names>P.</given-names></name>
<name><surname>Plebani</surname><given-names>M.</given-names></name>
</person-group><article-title>IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study</article-title><source>Clin. Chim. Acta.</source><year>2020</year><volume>507</volume><fpage>164</fpage><lpage>166</lpage><!--<pub-id pub-id-type="pmcid">PMC7194886</pub-id>--><pub-id pub-id-type="doi">10.1016/j.cca.2020.04.026</pub-id><pub-id pub-id-type="pmid">32343948</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01851"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brandtzaeg</surname><given-names>P.</given-names></name>
</person-group><article-title>Secretory IgA: Designed for Anti-Microbial Defense</article-title><source>Immunol. Front.</source><year>2013</year><volume>4</volume><fpage>222</fpage><!--<pub-id pub-id-type="pmcid">PMC3734371</pub-id>--><pub-id pub-id-type="doi">10.3389/fimmu.2013.00222</pub-id><pub-id pub-id-type="pmid">23964273</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01851"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bomsel</surname><given-names>M.</given-names></name>
<name><surname>Tudor</surname><given-names>D.</given-names></name>
<name><surname>Drillet</surname><given-names>A.S.</given-names></name>
<name><surname>Alfsen</surname><given-names>A.</given-names></name>
<name><surname>Ganor</surname><given-names>Y.</given-names></name>
<name><surname>Roger</surname><given-names>M.G.</given-names></name>
<name><surname>Mouz</surname><given-names>N.</given-names></name>
<name><surname>Amacker</surname><given-names>M.</given-names></name>
<name><surname>Chalifour</surname><given-names>A.</given-names></name>
<name><surname>Diomede</surname><given-names>L.</given-names></name>
</person-group><article-title>Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges</article-title><source>Immunity</source><year>2011</year><volume>34</volume><fpage>269</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.01.015</pub-id><pub-id pub-id-type="pmid">21315623</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01851"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khamassi</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Rey</surname><given-names>J.</given-names></name>
<name><surname>Duchemin</surname><given-names>M.</given-names></name>
<name><surname>Bouceba</surname><given-names>T.</given-names></name>
<name><surname>Tuffery</surname><given-names>P.</given-names></name>
<name><surname>Tudor</surname><given-names>D.</given-names></name>
<name><surname>Bomsel</surname><given-names>M.</given-names></name>
</person-group><article-title>The CH1&#x003b1; domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><elocation-id>e1009103</elocation-id><!--<pub-id pub-id-type="pmcid">PMC7802955</pub-id>--><pub-id pub-id-type="doi">10.1371/journal.ppat.1009103</pub-id><pub-id pub-id-type="pmid">33315937</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01851"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Butler</surname><given-names>S.E.</given-names></name>
<name><surname>Crowley</surname><given-names>A.R.</given-names></name>
<name><surname>Natarajan</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Weiner</surname><given-names>J.A.</given-names></name>
<name><surname>Bobak</surname><given-names>C.A.</given-names></name>
<name><surname>Mattox</surname><given-names>D.E.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Wieland-Alter</surname><given-names>W.</given-names></name>
<name><surname>Connor</surname><given-names>R.I.</given-names></name>
<etal/>
</person-group><article-title>Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals</article-title><source>Front. Immunol.</source><year>2021</year><volume>11</volume><elocation-id>618685</elocation-id><!--<pub-id pub-id-type="pmcid">PMC7876222</pub-id>--><pub-id pub-id-type="doi">10.3389/fimmu.2020.618685</pub-id><pub-id pub-id-type="pmid">33584712</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01851"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>H.Q.</given-names></name>
<name><surname>Sun</surname><given-names>B.Q.</given-names></name>
<name><surname>Fang</surname><given-names>Z.F.</given-names></name>
<name><surname>Zhao</surname><given-names>J.C.</given-names></name>
<name><surname>Liu</surname><given-names>X.Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.M.</given-names></name>
<name><surname>Sun</surname><given-names>X.Z.</given-names></name>
<name><surname>Liang</surname><given-names>H.F.</given-names></name>
<name><surname>Zhong</surname><given-names>B.</given-names></name>
<name><surname>Huang</surname><given-names>Z.F.</given-names></name>
<etal/>
</person-group><article-title>Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients</article-title><source>Eur. Respir. J.</source><year>2020</year><volume>56</volume><fpage>2001526</fpage><!--<pub-id pub-id-type="pmcid">PMC7236821</pub-id>--><pub-id pub-id-type="doi">10.1183/13993003.01526-2020</pub-id><pub-id pub-id-type="pmid">32398307</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01851"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zervou</surname><given-names>F.N.</given-names></name>
<name><surname>Louie</surname><given-names>P.</given-names></name>
<name><surname>Stachel</surname><given-names>A.</given-names></name>
<name><surname>Zacharioudakis</surname><given-names>I.M.</given-names></name>
<name><surname>Ortiz-Mendez</surname><given-names>Y.</given-names></name>
<name><surname>Thomas</surname><given-names>K.</given-names></name>
<name><surname>Aguero-Rosenfeld</surname><given-names>M.E.</given-names></name>
</person-group><article-title>SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection</article-title><source>J. Med. Virol.</source><year>2021</year><volume>93</volume><fpage>5409</fpage><lpage>5415</lpage><!--<pub-id pub-id-type="pmcid">PMC8242647</pub-id>--><pub-id pub-id-type="doi">10.1002/jmv.27058</pub-id><pub-id pub-id-type="pmid">33932299</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01851"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ejemel</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Hou</surname><given-names>S.</given-names></name>
<name><surname>Schiller</surname><given-names>Z.A.</given-names></name>
<name><surname>Tree</surname><given-names>J.A.</given-names></name>
<name><surname>Wallace</surname><given-names>A.</given-names></name>
<name><surname>Amcheslavsky</surname><given-names>A.</given-names></name>
<name><surname>Kurt</surname><given-names>Y.</given-names></name>
<name><surname>Buttigieg</surname><given-names>K.R.</given-names></name>
<name><surname>Elmore</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction</article-title><source>Nat Commun.</source><year>2020</year><volume>11</volume><fpage>4198</fpage><!--<pub-id pub-id-type="pmcid">PMC7442812</pub-id>--><pub-id pub-id-type="doi">10.1038/s41467-020-18058-8</pub-id><pub-id pub-id-type="pmid">32826914</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01851"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000f6;ritzer</surname><given-names>K.</given-names></name>
<name><surname>Groppelli</surname><given-names>E.</given-names></name>
<name><surname>Gr&#x000fc;nwald-Gruber</surname><given-names>C.</given-names></name>
<name><surname>Figl</surname><given-names>R.</given-names></name>
<name><surname>Ni</surname><given-names>F.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>Q.</given-names></name>
<name><surname>Puligedda</surname><given-names>R.D.</given-names></name>
<etal/>
</person-group><article-title>Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2</article-title><source>Mol. Ther.</source><year>2024</year><volume>32</volume><fpage>689</fpage><lpage>703</lpage><!--<pub-id pub-id-type="pmcid">PMC10928148</pub-id>--><pub-id pub-id-type="doi">10.1016/j.ymthe.2024.01.025</pub-id><pub-id pub-id-type="pmid">38268188</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01851-f001"><label>Figure 1</label><caption><p>SARS-CoV-2 IgA in BAL according to SOFA score in infected patients enrolled in ICU.</p></caption><graphic xlink:href="viruses-16-01851-g001" position="float"/></fig><fig position="float" id="viruses-16-01851-f002"><label>Figure 2</label><caption><p>SARS-CoV-2 IgA in BAL according to APACHE II score in infected patients enrolled in ICU.</p></caption><graphic xlink:href="viruses-16-01851-g002" position="float"/></fig><table-wrap position="float" id="viruses-16-01851-t001"><object-id pub-id-type="pii">viruses-16-01851-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinical demographic data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">57 Patients</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Anti SARS-CoV-2-IgA</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Survivors</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Not Survived</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive in BAL</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mean age</td><td align="center" valign="middle" rowspan="1" colspan="1">70.04 &#x000b1; 9.43 years</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Caucasian</td><td align="center" valign="middle" rowspan="1" colspan="1">All</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Males</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Females</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Comorbidities</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Arterial hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Obesity</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cardiovascular diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COPD</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Allergy</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Renal failure/cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Asthma</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Liver diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterial infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-16-01851-t002"><object-id pub-id-type="pii">viruses-16-01851-t002_Table 2</object-id><label>Table 2</label><caption><p>The APACHE and SOFA scores in SARS-CoV-2 selected patients tested for the presence of anti-SARS-CoV-2 IgA in BAL.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">APACHE II</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Anti-SARS-CoV-2 IgA</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Anti-SARS-CoV-2 IgA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;10</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (67%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (33%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11&#x02013;20</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (67%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (40%)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (60%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (33%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (67%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SOFA</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-SARS-CoV-2 IgA</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-SARS-CoV-2 IgA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;3</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (46%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (53%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (47%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02013;7</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (51%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (59%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8&#x02013;10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr></tbody></table></table-wrap></floats-group></article>